This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study of muraglitazar and adverse events by Dr Nissen and colleagues¹ points out why physicians need hard outcomes data obtained in a blinded fashion before prescribing a new therapy for patients. The study, however, raises broader concerns beyond muraglitazar. Mortality data are needed prior to US Food and Drug Administration (FDA) approval for peroxisome proliferator–activated receptor (PPAR) agonists, and current practices that use combined therapy for patients with diabetes who have lipid abnormalities need to be examined.

There is a relative paucity of mortality data for fibric acid derivatives compared with data on statins. One of the 3 large studies examining the use of gemfibrozil in the secondary prevention of cardiovascular disease showed a nonstatistically significant 7% increase in total mortality.² Another study showed a nonsignificant benefit for gemfibrozil, with a 10% reduction in total mortality.³ Bezafibrate was reported to have a nonsignificant 6% higher mortality.⁴ . . . [Full Text of this Article]

David M. Najman, MD
heartdr@northwestern.edu
Evanston Northwestern Healthcare
Skokie, Ill

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Adverse Events Related to Muraglitazar Use in Diabetes
David Parra, Cherylyn Beckey, and Thomas Thomas
JAMA. 2006;295(17):1997-1998.
EXTRACT | FULL TEXT  

Adverse Events Related to Muraglitazar Use in Diabetes—Reply
Steven E. Nissen
JAMA. 2006;295(17):1998.
EXTRACT | FULL TEXT  

Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Steven E. Nissen, Kathy Wolski, and Eric J. Topol
JAMA. 2005;294(20):2581-2586.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008)
NAJMAN
Cleveland Clinic Journal of Medicine 2009;76:83-83.
FULL TEXT